Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.48), versus ($0.09) reported last year. Revenue for the quarter came in at $2.9 million versus the consensus estimate of $679 thousand.

• Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development
• First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next Quarter
• Continued Progress in the Commercialization of alfataliglicerase in Brazil

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.